Cellectar Biosciences Inc Share Price Nasdaq
Equities
US15117F3029
Pharmaceuticals
Sales 2024 * | - | Sales 2025 * | 44.27M 3.54B | Capitalization | 110M 8.79B |
---|---|---|---|---|---|
Net income 2024 * | -49M -3.91B | Net income 2025 * | -22M -1.76B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.49 x |
P/E ratio 2024 * |
-1.88
x | P/E ratio 2025 * |
-5.32
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.19% |
Latest transcript on Cellectar Biosciences Inc
Managers | Title | Age | Since |
---|---|---|---|
James V. Caruso
CEO | Chief Executive Officer | 65 | 14/06/15 |
Chad J. Kolean
DFI | Director of Finance/CFO | 59 | 27/05/14 |
Andrei Shustov
CTO | Chief Tech/Sci/R&D Officer | - | 14/02/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Driscoll
BRD | Director/Board Member | 74 | 06/04/17 |
Douglas Swirsky
CHM | Chairman | 54 | 06/04/17 |
John Neis
BRD | Director/Board Member | 68 | 31/01/08 |
1st Jan change | Capi. | |
---|---|---|
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |